{"FP": [{"generated": ["16 \u00d7 10 cm"], "gold": [], "text": "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space."}, {"generated": ["prolonged life expectancy"], "gold": [], "text": "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8]."}, {"generated": ["early in the morning"], "gold": [], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": ["two decades"], "gold": ["the past two decades"], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": ["29%", "83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["29%", "83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["very narrow therapeutic indices"], "gold": [], "text": "An important fact is that most of these affected drugs have very narrow therapeutic indices."}, {"generated": ["last decade"], "gold": [], "text": "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2]."}, {"generated": ["time course", "time"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["time course", "time"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["44"], "gold": [], "text": "[44]."}, {"generated": ["NADP Phytofingerprinting", "serial dilutions", "column oven", "UPLC system"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["NADP Phytofingerprinting", "serial dilutions", "column oven", "UPLC system"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["NADP Phytofingerprinting", "serial dilutions", "column oven", "UPLC system"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["NADP Phytofingerprinting", "serial dilutions", "column oven", "UPLC system"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["96 hours"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["not specified"], "gold": [], "text": "Elliot et al."}, {"generated": ["2003"], "gold": [], "text": "(2003)."}, {"generated": ["not specified"], "gold": [], "text": "Park et al."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["in vivo distribution studies"], "gold": [], "text": "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22]."}, {"generated": ["42 mg\u00b7kg"], "gold": [], "text": "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD)."}, {"generated": ["2017-07-30"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["30 min"], "gold": [], "text": "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c)."}, {"generated": ["\u221220\u00b0C until analysis", "subsequently"], "gold": [], "text": "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis."}, {"generated": ["\u221220\u00b0C until analysis", "subsequently"], "gold": [], "text": "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis."}, {"generated": ["duration of events found in text"], "gold": [], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": ["pretreatment"], "gold": [], "text": "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel."}, {"generated": ["risk of tumour progression"], "gold": [], "text": "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer."}, {"generated": ["15 minutes", "20 minutes"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["15 minutes", "20 minutes"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["16 subjects", "27 adverse events"], "gold": [], "text": "Sixteen subjects reported 27 adverse events."}, {"generated": ["16 subjects", "27 adverse events"], "gold": [], "text": "Sixteen subjects reported 27 adverse events."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["equal volume", "100 mg"], "gold": [], "text": "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer."}, {"generated": ["equal volume", "100 mg"], "gold": [], "text": "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer."}, {"generated": ["2 hours"], "gold": [], "text": "Pharmacokinetic studies started 2 h after the last RGE treatment."}, {"generated": ["Not applicable"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["2014"], "gold": [], "text": "2014; Dybro et\u00a0al."}, {"generated": ["3.5 \u03bcm"], "gold": [], "text": "; 3.5\u2009\u03bcm) at room temperature."}, {"generated": ["10 min"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["metabolic rate of AC", "maximum plasma concentration"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["metabolic rate of AC", "maximum plasma concentration"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["tExperimental values", "half-life", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["tExperimental values", "half-life", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["tExperimental values", "half-life", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["tExperimental values", "half-life", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["not specified"], "gold": [], "text": "In the present study, the selectivity was examined using independent plasma samples from six different rats."}, {"generated": ["QRS interval prolongation", "after the administration of C. pinnatifida Bunge (Shanzha) extract", "ventricular tachycardia", "ventricular fibrillation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["QRS interval prolongation", "after the administration of C. pinnatifida Bunge (Shanzha) extract", "ventricular tachycardia", "ventricular fibrillation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["QRS interval prolongation", "after the administration of C. pinnatifida Bunge (Shanzha) extract", "ventricular tachycardia", "ventricular fibrillation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["QRS interval prolongation", "after the administration of C. pinnatifida Bunge (Shanzha) extract", "ventricular tachycardia", "ventricular fibrillation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["QRS interval prolongation", "after the administration of C. pinnatifida Bunge (Shanzha) extract", "ventricular tachycardia", "ventricular fibrillation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["phase I (NCT03929250, NCT03937908)", "proposed phase II clinical trials"], "gold": [], "text": "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline."}, {"generated": ["phase I (NCT03929250, NCT03937908)", "proposed phase II clinical trials"], "gold": [], "text": "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline."}, {"generated": ["C. asiatica"], "gold": [], "text": "C. asiatica Plant Material and Preparation of CAW-R61J."}, {"generated": ["shipped", "frozen", "lyophilized"], "gold": [], "text": "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2)."}, {"generated": ["shipped", "frozen", "lyophilized"], "gold": [], "text": "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2)."}, {"generated": ["shipped", "frozen", "lyophilized"], "gold": [], "text": "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2)."}, {"generated": ["thawed at ambient temperature"], "gold": [], "text": "Plates were thawed at ambient temperature."}, {"generated": ["using Prism 8.0.2"], "gold": [], "text": "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA)."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["triplicate determinations"], "gold": [], "text": "of triplicate determinations."}, {"generated": ["chronic kidney disease"], "gold": [], "text": "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14]."}, {"generated": ["24 h"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["jejunal segments"], "gold": [], "text": "The jejunal segments were then isolated and rinsed using pre-warmed saline."}, {"generated": ["product ion scan results", "previously published reports"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["product ion scan results", "previously published reports"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["inter- and intra-day accuracy", "slight variations in the analytical process", "variability in the performance of the analytical instrument", "changes in recovery during preparation of a biological sample"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["inter- and intra-day accuracy", "slight variations in the analytical process", "variability in the performance of the analytical instrument", "changes in recovery during preparation of a biological sample"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["inter- and intra-day accuracy", "slight variations in the analytical process", "variability in the performance of the analytical instrument", "changes in recovery during preparation of a biological sample"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["inter- and intra-day accuracy", "slight variations in the analytical process", "variability in the performance of the analytical instrument", "changes in recovery during preparation of a biological sample"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["different mass fragmentation patterns"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["mean and CV", "five or six independent experiments"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["mean and CV", "five or six independent experiments"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["chronic nature of HAART administration"], "gold": [], "text": "However, there are several challenges associated with the chronic nature of HAART administration."}, {"generated": ["24 h", "72 h", "same volume of purified water"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["24 h", "72 h", "same volume of purified water"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["24 h", "72 h", "same volume of purified water"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["final manuscript"], "gold": [], "text": "All authors reviewed the final manuscript."}, {"generated": ["7 \u00b1 1-day washout period"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["this dose"], "gold": [], "text": "Therefore, we applied this dose of GGT in our study."}, {"generated": ["a week"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["1000 mg", "4 times a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["1000 mg", "4 times a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["duration of events found in text"], "gold": [], "text": "and Y.C.P."}, {"generated": ["five days"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["45"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["Postsupplementation", "Presupplementation"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["Postsupplementation", "Presupplementation"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["earlier study"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["54"], "gold": [], "text": "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort."}, {"generated": ["12", "11"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["12", "11"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["little effect"], "gold": [], "text": "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study."}, {"generated": ["overnight fast", "single oral dose"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["overnight fast", "single oral dose"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["1, 2, 3, 4, 6, 8, 12, 24, 36, 48 h"], "gold": [], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": [], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": [], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": ["delayed and decreased absorption", "significant reduction in the Cmax and tmax", "no significant change in parameters indicative of interference with elimination"], "gold": [], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": ["delayed and decreased absorption", "significant reduction in the Cmax and tmax", "no significant change in parameters indicative of interference with elimination"], "gold": [], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": ["delayed and decreased absorption", "significant reduction in the Cmax and tmax", "no significant change in parameters indicative of interference with elimination"], "gold": [], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": ["not altered significantly"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["events of duration"], "gold": [], "text": "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials."}, {"generated": ["Stage 2"], "gold": [], "text": "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo."}, {"generated": ["events over time"], "gold": [], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": ["acute kidney injury"], "gold": [], "text": "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury."}, {"generated": ["27"], "gold": [], "text": "[27] In the study performed by Roozbeh et al."}, {"generated": ["2 months"], "gold": [], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["at least 6 min"], "gold": [], "text": "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min."}, {"generated": ["each blood sampling time before and after warfarin dosing"], "gold": [], "text": "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser."}, {"generated": ["clotting time"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["ln 2/kel", "dose/AUC0-\u221e", "CL/kel"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["ln 2/kel", "dose/AUC0-\u221e", "CL/kel"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["ln 2/kel", "dose/AUC0-\u221e", "CL/kel"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["two-compartment pharmacokinetic model", "S-warfarin concentration-time data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "S-warfarin concentration-time data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["about 600 mg"], "gold": [], "text": "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets."}, {"generated": ["described entities"], "gold": [], "text": "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results."}, {"generated": ["36"], "gold": [], "text": "[36]."}, {"generated": ["12 weeks", "4 weeks", "15 days"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["drug-induced cardiopulmonary toxicity"], "gold": [], "text": "This was an important case of drug-induced cardiopulmonary toxicity."}, {"generated": ["date of onset", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["date of onset", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["fully recovered"], "gold": [], "text": "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group."}, {"generated": ["long period"], "gold": [], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["120-fold variability", "13-fold variability"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["120-fold variability", "13-fold variability"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["previous study"], "gold": [], "text": "The previous study performed by Du et al."}, {"generated": ["10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0 to 48 h"], "gold": [], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": ["\u00b11 day"], "gold": ["\u00b11\u00a0day"], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["markedly"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["about 4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["compared to other groups"], "gold": [], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": ["end of the dosing interval"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["<50 copies/ml at the end of the study"], "gold": [], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": ["8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["same way"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["120 mg twice daily (b.i.d.)"], "gold": [], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "steady state", "sufficient to eventually induce CYPs", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "steady state", "sufficient to eventually induce CYPs", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "steady state", "sufficient to eventually induce CYPs", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "steady state", "sufficient to eventually induce CYPs", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["trials", "clinical data", "events"], "gold": [], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": ["trials", "clinical data", "events"], "gold": [], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": ["trials", "clinical data", "events"], "gold": [], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": ["onset of drug action", "duration of drug metabolism", "duration of drug effect", "duration of drug action", "half-life of drug"], "gold": [], "text": "Type of participant."}, {"generated": ["onset of drug action", "duration of drug metabolism", "duration of drug effect", "duration of drug action", "half-life of drug"], "gold": [], "text": "Type of participant."}, {"generated": ["onset of drug action", "duration of drug metabolism", "duration of drug effect", "duration of drug action", "half-life of drug"], "gold": [], "text": "Type of participant."}, {"generated": ["onset of drug action", "duration of drug metabolism", "duration of drug effect", "duration of drug action", "half-life of drug"], "gold": [], "text": "Type of participant."}, {"generated": ["onset of drug action", "duration of drug metabolism", "duration of drug effect", "duration of drug action", "half-life of drug"], "gold": [], "text": "Type of participant."}, {"generated": ["standard eligibility inclusion criteria"], "gold": [], "text": "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers."}, {"generated": ["events of events found in text"], "gold": [], "text": "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2."}, {"generated": ["[21\u201324, 26, 28, 29]"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["45.6%", "36.5%", "61.5%"], "gold": [], "text": "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%."}, {"generated": ["45.6%", "36.5%", "61.5%"], "gold": [], "text": "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%."}, {"generated": ["45.6%", "36.5%", "61.5%"], "gold": [], "text": "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%."}, {"generated": ["", "multiple reasons"], "gold": [], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": ["", "multiple reasons"], "gold": [], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": ["dose-dependent manner"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["every study day"], "gold": [], "text": "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day."}, {"generated": ["terminal elimination rate constant (\u03bb"], "gold": [], "text": "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute)."}, {"generated": ["silibinin predosing", "multiple dosing of raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["silibinin predosing", "multiple dosing of raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["human [63\u201365]"], "gold": [], "text": "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365]."}, {"generated": ["two children"], "gold": [], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": ["long-term basis"], "gold": [], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": ["notoginsenoside R UPLC-MS/MS analysis"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["2 \u00d7 10"], "gold": [], "text": "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China)."}, {"generated": ["p < 0.001", "p < 0.01"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["p < 0.001", "p < 0.01"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["up to a dilution of 1%"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["described", "events", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["described", "events", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["described", "events", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["events of events found in text"], "gold": [], "text": "Results of the reporter gene assays."}, {"generated": ["original formulation"], "gold": [], "text": "Its original formulation was in a tablet form."}, {"generated": ["2 weeks"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["500\u00b0C"], "gold": [], "text": "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C."}, {"generated": ["no clinically significant alterations"], "gold": [], "text": "No clinically significant alterations in blood pressure, heart rate or body temperature were observed."}, {"generated": ["7th day", "7 days"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["7th day", "7 days"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["2 hours", "7 days"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 hours", "7 days"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["events of duration"], "gold": [], "text": "All authors have read and agreed to the published version of the manuscript."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average \u00b1 SD", "periods of time", "lengths of time", "time spans", "time intervals", "duration of events"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["5 minutes"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["significant dosage differences"], "gold": [], "text": "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group."}, {"generated": ["process of database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["process of database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["not specified"], "gold": [], "text": "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49]."}, {"generated": ["Table S4"], "gold": [], "text": "Table S4."}, {"generated": ["time intervals in pharmacokinetic studies", "duration of drug action", "duration of events related to pharmacological studies", "duration of pharmacological effects", "time frames in pharmacodynamic studies"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["time intervals in pharmacokinetic studies", "duration of drug action", "duration of events related to pharmacological studies", "duration of pharmacological effects", "time frames in pharmacodynamic studies"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["time intervals in pharmacokinetic studies", "duration of drug action", "duration of events related to pharmacological studies", "duration of pharmacological effects", "time frames in pharmacodynamic studies"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["time intervals in pharmacokinetic studies", "duration of drug action", "duration of events related to pharmacological studies", "duration of pharmacological effects", "time frames in pharmacodynamic studies"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["time intervals in pharmacokinetic studies", "duration of drug action", "duration of events related to pharmacological studies", "duration of pharmacological effects", "time frames in pharmacodynamic studies"], "gold": [], "text": "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All."}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": [], "text": "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig."}, {"generated": ["durations of events"], "gold": [], "text": "(PDF 36 kb) Figure S2."}, {"generated": ["Springer Nature"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["two weeks"], "gold": ["for two weeks"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["before blood collection process"], "gold": [], "text": "The animals were anaesthetized before blood collection process."}, {"generated": ["1.0 mL"], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["ranged from 1.56% to 14.38%"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["reaction"], "gold": [], "text": "The reaction was then stopped by adding formic acid [17]."}, {"generated": ["2016"], "gold": [], "text": "2016)."}, {"generated": ["ad libitum"], "gold": [], "text": "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum."}, {"generated": ["Agilent 1290 series"], "gold": [], "text": "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA)."}, {"generated": ["duration of events found in text"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["the course of his treatment"], "gold": [], "text": "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment."}, {"generated": ["seven days", "next processing"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["seven days", "next processing"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["3a", "3b"], "gold": [], "text": "3a and b)."}, {"generated": ["3a", "3b"], "gold": [], "text": "3a and b)."}, {"generated": ["0.642min", "SITA", "PRM", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["0.642min", "SITA", "PRM", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["0.642min", "SITA", "PRM", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["0.642min", "SITA", "PRM", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["mean \u00b1 SEM"], "gold": [], "text": "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats."}, {"generated": ["9 months"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["six rats"], "gold": [], "text": "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["18\u201328 hours", "0\u20136 hours", "6\u201318 hours"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["18\u201328 hours", "0\u20136 hours", "6\u201318 hours"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["18\u201328 hours", "0\u20136 hours", "6\u201318 hours"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["plasma concentration-time curves", "time", "changing trends"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["plasma concentration-time curves", "time", "changing trends"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["plasma concentration-time curves", "time", "changing trends"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["monthly INR monitoring"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["375 ml"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["3 days"], "gold": ["for 3 days"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["7.2 hours"], "gold": [], "text": "7.2."}, {"generated": ["extremely high doses"], "gold": [], "text": "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses."}, {"generated": ["placed the tubes on a cooling block"], "gold": [], "text": "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)."}, {"generated": ["chronic exposure"], "gold": [], "text": "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["0.05", "0.001", "0.01"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["0.05", "0.001", "0.01"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["0.05", "0.001", "0.01"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["PT time", "reduction in the warfarin plasma concentration"], "gold": [], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": ["PT time", "reduction in the warfarin plasma concentration"], "gold": [], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": ["several case reports"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["not specified"], "gold": [], "text": "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54]."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["moderately"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["highest dose of the extract"], "gold": [], "text": "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees approved the protocol (approval No.)"], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["half-maximal inhibitory concentration (IC50)", "ethics committees approved the protocol (approval No.)"], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["sequentially numbered"], "gold": [], "text": "Double-blinded treatments were allocated using sequentially numbered drug containers."}, {"generated": ["P < 0.05"], "gold": [], "text": "A difference was considered significant at P < 0.05."}, {"generated": ["ranged from 1 to 23 ng ml\u22121"], "gold": [], "text": "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121."}, {"generated": ["not specified"], "gold": [], "text": "Gorski et al."}, {"generated": ["35"], "gold": [], "text": "[35]."}, {"generated": ["periods", "duration", "worsening", "events"], "gold": [], "text": "Worse than the Disease?"}, {"generated": ["periods", "duration", "worsening", "events"], "gold": [], "text": "Worse than the Disease?"}, {"generated": ["periods", "duration", "worsening", "events"], "gold": [], "text": "Worse than the Disease?"}, {"generated": ["periods", "duration", "worsening", "events"], "gold": [], "text": "Worse than the Disease?"}, {"generated": ["Five days"], "gold": [], "text": "Five days after presentation, her symptoms had completely resolved."}, {"generated": ["exposure", "antihistamines", "refractory", "resolved"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["exposure", "antihistamines", "refractory", "resolved"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["exposure", "antihistamines", "refractory", "resolved"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["exposure", "antihistamines", "refractory", "resolved"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["30 minutes"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["ten marker components"], "gold": [], "text": "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs."}, {"generated": ["decrease", "significantly increase"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["decrease", "significantly increase"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["after co-administration with RS"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["62%"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["2000\u20132019"], "gold": [], "text": "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)."}, {"generated": ["approximately 60%"], "gold": [], "text": "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990)."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["approximately 1%", "1990", "approximately 10%"], "gold": [], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": ["approximately 1%", "1990", "approximately 10%"], "gold": [], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": ["approximately 1%", "1990", "approximately 10%"], "gold": [], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": ["duration of events found in text"], "gold": [], "text": "Click here for additional data file."}, {"generated": ["similar laboratory environmental conditions"], "gold": [], "text": "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity."}, {"generated": ["100 mm"], "gold": [], "text": "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm)."}, {"generated": ["incremental protocol", "24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["incremental protocol", "24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["incremental protocol", "24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["longitudinal YM effectiveness"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["ad libitum"], "gold": [], "text": "Food and water were supplied ad libitum."}, {"generated": ["chronic use"], "gold": [], "text": "Chronic use of ginseng on its own has been associated with manic psychosis [90]."}, {"generated": ["orally administered"], "gold": [], "text": "This is important because the vast majority of herbal products are orally administered."}, {"generated": ["durations of events"], "gold": [], "text": "This is especially important for drugs with a narrow therapeutic window."}, {"generated": ["initial and final versions of the manuscript"], "gold": [], "text": "Author contributions: MK drafted the initial and final versions of the manuscript."}, {"generated": ["15 minutes"], "gold": [], "text": "et Zucc.)"}, {"generated": ["evaporated to dryness"], "gold": [], "text": "The combined extraction solution was then evaporated to dryness."}, {"generated": ["often over years"], "gold": [], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": ["short-term", "time until surgical intervention"], "gold": [], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["short-term", "time until surgical intervention"], "gold": [], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["2\u20133 days"], "gold": [], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": ["hints to possible beneficial effects"], "gold": [], "text": "This is debated, and there are hints to possible beneficial effects [135]."}, {"generated": ["not specified"], "gold": [], "text": "Seong et al."}, {"generated": ["2018"], "gold": [], "text": "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use."}, {"generated": ["3 weeks"], "gold": ["after 3 weeks"], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}, {"generated": ["weekly"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["durations of events"], "gold": [], "text": "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["two millennia"], "gold": [], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": ["further research"], "gold": [], "text": "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels."}, {"generated": ["98"], "gold": [], "text": "no interaction [98]."}, {"generated": ["Springer Nature"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["several studies"], "gold": [], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": ["one-way analysis of variance (ANOVA)", "Post hoc Scheffe\u2019s multiple comparison test"], "gold": [], "text": "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05."}, {"generated": ["one-way analysis of variance (ANOVA)", "Post hoc Scheffe\u2019s multiple comparison test"], "gold": [], "text": "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05."}, {"generated": ["25 \u03bcg/ml concentration"], "gold": [], "text": "The activation was highest at 25\u00a0\u03bcg/ml concentration."}, {"generated": ["in vivo study"], "gold": [], "text": "The in vivo study was conducted on healthy human volunteers."}, {"generated": ["clinical study"], "gold": [], "text": "Therefore, the clinical study was conducted to confirm the in vitro results."}, {"generated": ["outcomes", "quality of life", "long-term", "short-term", "event-related"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["outcomes", "quality of life", "long-term", "short-term", "event-related"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["outcomes", "quality of life", "long-term", "short-term", "event-related"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["outcomes", "quality of life", "long-term", "short-term", "event-related"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["outcomes", "quality of life", "long-term", "short-term", "event-related"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["recently"], "gold": [], "text": "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient."}], "FN": [{"generated": ["two decades"], "gold": ["the past two decades"], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": [], "gold": ["for 1 or 2 weeks"], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": [], "gold": ["30-minute"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": ["24 h", "72 h", "same volume of purified water"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["a week"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": [], "gold": ["for 5 days"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": [], "gold": ["14 subsequent days"], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": [], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["1-week"], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": ["\u00b11 day"], "gold": ["\u00b11\u00a0day"], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "steady state", "sufficient to eventually induce CYPs", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": [], "gold": ["for thousands of years"], "text": "Herbs have been used for primary health care for thousands of years before the advent of modern medicines."}, {"generated": [], "gold": ["after four days"], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["7th day", "7 days"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["2 hours", "7 days"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["two weeks"], "gold": ["for two weeks"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["3 days"], "gold": ["for 3 days"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": [], "gold": ["30 days"], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": [], "gold": ["for thousands of years"], "text": "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014)."}, {"generated": ["3 weeks"], "gold": ["after 3 weeks"], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}]}